A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

Overview of attention for article published in Clinical Cancer Research, May 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 1 news outlet
twitter: 18 X users

f1000: 1 research highlight platform

Citations

dimensions_citation: 104 Dimensions

Readers on

mendeley: 92 Mendeley

Summary News X Research highlights Dimensions citations

So far, Altmetric has seen 1 review on a research highlight platform.

Recommended in Faculty Opinions

02 Nov 2020

This research output was recommended by a member of Faculty Opinions.

This page shows the most recent research highlights that mention this research output.

Click here to find out how to access more activity.